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Context: Overweight and obesity are overrepresented in adolescents
with type 1 diabetes mellitus (T1DM). Exogenous insulin adminis-
tration often poorly reproduces normal insulin patterns and may less
effectively regulate leptin and ghrelin, two hormones involved in the
control of appetite and adiposity.
Objective: The objective of the study was to determine whether
insulin regimens that better replicate normal insulin patterns and
augment postprandial nutrient disposal may help normalize leptin
and ghrelin and improve body weight regulation.
Design, Setting, and Participants: Ten young women with T1DM
were studied in this 2-wk prospective, balanced crossover-design
study at the University of California, Davis.
Intervention: Participants received either a single injection of
regular ! NPH insulin (R!N) or two mealtime injections of Lispro
insulin in randomized order on 2 separate days. Meal composition
and total insulin administered were the same on both treatment
days.
Main Outcome Measures: Plasma glucose, insulin, leptin, and
ghrelin concentrations were monitored over the 10-h study period.
Results: Lispro produced two distinct mealtime peaks of insulin, com-
pared with one prolonged rise with R!N. Lispro reduced postprandial
hyperglycemia and total glucose area under the curve. Leptin increased
more on the Lispro (2.7" 0.7 vs. 0.7" 0.5 ng/ml, P# 0.02). Ghrelin was
more suppressed after lunch with Lispro (P # 0.004).
Conclusions: Injection of Lispro insulin with meals produces more
physiological insulin patterns, better glucose control, and improved
leptin and ghrelin regulation than R!N. More closely mimicking
normal insulin, leptin, and ghrelin responses to meals with fast-
acting insulin may have implications for body weight regulation in
T1DM. (J Clin Endocrinol Metab 91: 485–491, 2006)
YOUNG INDIVIDUALS WITH type 1 diabetes mellitus(T1DM), particularly adolescent females, have an in-
creased prevalence of overweight and obesity (1–3), placing
them at greater risk for metabolic complications. This ob-
servation is somewhat surprising given that these patients
are susceptible to severe catabolic states when insufficient
insulin is administered. Excessweight in patientswith T1DM
is associated with both twice-daily and multiple-daily injec-
tion insulin regimens as well as less rigorous adherence to
dietary recommendations (2–4). In the short term, rapid im-
provement of glycemic control is often associated with
weight gain, as was seen in the first year of the Diabetes
Control and Complications trial (5). This has commonly at-
tributed to a variety of factors, including a reduction in
catabolism, diminished caloric loss from glucosuria, and in-
creased energy intake triggered by more frequent episodes
of hypoglycemia that can occur with more intensive therapy.
However, reports are conflicting with regard to the associ-
ation of metabolic control or total insulin dose and long-term
weight control (1, 5, 6), leaving the underlying cause for
increased overweight/obesity in T1DM unresolved. One po-
tential explanation is that the endocrine systems involved in
regulation of appetite and bodyweightmay be dysfunctional
in T1DM. A vast array of hormonal and neural signaling
pathways control food intake and energy expenditure, and
insulin is implicated in this process at multiple levels (7, 8).
Insulin regulates, at least in part, the hormones leptin and
ghrelin. Leptin and ghrelin are two key factors in the control
of energy balance (9, 10), and therefore, a lack of normal
physiological regulation of these endocrine signals may have
a role in overweight andobesity in T1DM.Leptin is produced
by adipocytes in proportion to adipose tissue mass and
recent energy intake. It serves as a signal of long-term
energy status to the brain, acting to decrease food intake
and enhance energy expenditure (11). Ghrelin is an acy-
lated peptide secreted from endocrine cells in the stomach
and upper intestine (12, 13). Ghrelin’s actions on energy
balance are opposite to those of leptin, and ghrelin acti-
vates rather than inhibits hypothalamic neuropeptide
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Y/agouti gene-related peptide signaling (14). Ghrelin en-
hances appetite and increases food intake (15). In concert,
leptin and ghrelin serve as vital regulators of energy
homeostasis.
Based on the evidence that insulin, glucose, and glucose
metabolism are involved in the regulation of leptin and
ghrelin, we hypothesized that alterations in normal post-
prandial insulin excursions (and therefore nutrient disposal)
might result in dysfunctional regulation of the postprandial
stimulation of leptin production and suppression of ghrelin
secretion. In the long term, this dysregulation could contrib-
ute to abnormal weight gain and overweight/obesity in pa-
tients with T1DM.
Many patients with T1DM are managed with conventional
insulin therapy, using twice-daily injections of a mixture of
fast-acting and intermediate-acting insulin preparations, often
regular andneutral protamineHagedorn (NPH). Thepatternof
circulating insulin levels with this type of regimen is markedly
different from that in nondiabetic individuals, in whom insulin
levels increase rapidly and then quickly decline after eachmeal.
Newer, more rapid-acting and shorter-acting insulin analogs
make it possible to more closely reproduce the normal insulin
responses to meals. We sought to determine whether two in-
jections of rapid-acting Lispro insulin before breakfast and
lunch would result in enhanced leptin production and more
pronounced postprandial suppression of ghrelin, compared
with amore conventional regimen of a singlemorning injection
of the same total number of units of regular and NPH (R!N)
in patients with T1DM. Insulin regimens that better replicate
normal postprandial insulin responses could enhance the en-
docrine regulation of energy balance and reduce the predispo-
sition to overweight and obesity. These results would have
important therapeutic implications for the treatment of patients
with T1DM.
Subjects and Methods
Subjects and subject selection
Twelve female subjects with T1DM [Tanner stage V: age 14–32 yr,
body mass index (BMI) 24.5 " 1.9 kg/m2, range 17–35 kg/m2, percent
body fat 30 " 3%] were recruited from the Pediatric and Young Adult
Diabetes Clinics of the University of California, Davis, Medical Center
and advertisements on the University of California, Davis campus. Only
individuals currently using Lispro insulin were included in the study.
Most patients were using continuous sc insulin infusion via insulin
pumps. Subjects using a combination of Lispro and NPH insulin were
included only if their evening insulin was taken before 1700 h (n # 2)
to eliminate potential effects of residually acting NPH insulin. Subjects
with chronic diseases other than diabetes were excluded.
Only female subjects were included in the study because young
female patients with T1DM have a higher prevalence of overweight/
obesity than males. In addition, women have higher circulating plasma
leptin concentrations and larger leptin responses to meal-induced in-
sulin secretion than men (16, 17). Therefore, changes of circulating leptin
in response to differing insulin regimens would be more readily de-
tectable in female subjects. The Institutional Review Board of University
of California, Davis approved the experimental protocol, and subjects
provided informed consent to participate in the study.
Experimental protocol
The study was a balanced crossover design in which patients were
studied on 2 randomized experimental days, approximately 1 wk apart.
On 1 study day, subjects received the conventional insulin treatment
(R!N). On the other study day, subjects received Lispro insulin with
each of the two meals served. The conventional treatment consisted of
a single sc injection of premixed NPH and regular recombinant human
insulin (Humulin 70/30; Eli Lilly, Indianapolis, IN) self-administered in
the abdominal region before breakfast (0900 h). On the Lispro treatment
day the subjects administered two injections of Lispro insulin (Eli Lilly)
of equivalent dosage, one with breakfast and one with lunch. The insulin
dose was calculated according to each individual subject’s usual regi-
men and was determined by multiplying the patient’s prescribed ratio
of Lispro insulin to carbohydrate (units insulin per gram carbohydrate)
by the grams of carbohydrate in the meals provided. The total amount
of insulin administered did not differ between the R!N (26.3 " 3.7 U)
and the Lispro treatment days (26.0 " 3.7 U).
The meals were designed to provide appropriate caloric intake for
each individual based on maintenance energy requirements, with equal
amounts of carbohydrates and total calories at breakfast and lunch. The
meals consisted of whole foods providing 60% of energy as carbohy-
drate, 20% as fat, and 20% as protein. The same meals were fed on each
study day. After an overnight fast, subjects arrived at the Pediatric
Infusion Center between 0715 and 0730 h to begin the protocol. Subjects
using insulin pumps were instructed to turn the pump off at 0700 h.
Subjects using a combination of Lispro and NPH insulin were instructed
to inject NPH insulin at the same time in the evening before each of the
2 study days (before 1700 h).
Body weight and height were determined on arrival to the Infusion
Center. Body composition was determined by bioelectrical impedance
analysis (Bodystat, Isle of Man, UK). An iv catheter was placed in an arm
vein and kept patent by the slow infusion of 0.9% normal saline through-
out the study. Blood sampling began at 0800 h, and samples were taken
every 30 min for 10 h, except for 1 h after each meal, during which
samples were taken at 15-min intervals to define better the postprandial
insulin and glucose concentrations. The subjects were given breakfast at
0900 h and lunch at 1300 h. Subjects were permitted free access to water.
Blood glucose was monitored at bedside throughout the day with a
glucometer to ensure subjects did not become hypoglycemic.
Biochemical analyses
Plasma glucose was determined with a YSI glucose analyzer (Yellow
Springs Instruments, Yellow Springs, OH). Plasma leptin was measured
using a RIA kit from Linco Research, Inc. (St. Charles, MO). Insulin was
measured using RIA as previously described (18) with insulin tracer
purchased from Amersham Biosciences (Piscataway, NJ) and antibody
purchased from RadioAssay System Laboratories (Carson, CA). This
antibody is fully cross-reactive with Lispro, NPH, and regular insulin.
All samples from each subject were run within the same assay. Total
immunoreactive ghrelin was determined with our modification of a
commercial RIA (Phoenix Pharmaceuticals, Belmont, CA). This assay
uses a 125-I-labeled ghrelin tracer and a rabbit polyclonal antibody
against full-length, octanoylated human ghrelin that recognizes the acy-
lated and des-acyl forms. Although only acylated ghrelin is bioactive
(13), total ghrelin appears to be a reasonable surrogate for the acylated
form because the ratio of the two levels remains constant under a wide
variety of conditions that affect ghrelin (19, 20). The lower and upper
detection limits were 80 and 2500 pg/ml, respectively, and the inter- and
intraassay coefficients of variation were 5.9 and 10.3%, respectively.
Calculations and statistical analysis
Twelve female subjects participated in the study. Data from two
subjectswere not included because the difference in day-long circulating
insulin concentrations between the 2 treatment days was greater than
45%. The difference likely resulted from poor insulin injection technique
leading to impaired insulin absorption on 1 study day. The data pre-
sented are from the 10 subjects in which the mean insulin concentration
differed by less than 25% between the 2 study days.
Total leptin responses were determined by calculating the integrated
leptin area-over-nadir levels [area under the curve (AUC)]. This is done
by subtracting themean nadir value (average of three lowest consecutive
morning samples) and calculating the AUC over 10 h using the trape-
zoidal method, as previously described (21). The integrated ghrelin
response tomealswas determined by calculating the area under premeal
nadir levels (AUC). The total AUC above baseline levels for both insulin
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and glucose was also calculated. Paired t tests were performed and
significance was set at P % 0.05. Results are presented as mean " sem.
Results
Insulin
As expected, the pattern of circulating insulin concentra-
tions differed markedly between the two insulin regimens
(Fig. 1A). Plasma insulin levels increased similarly after
breakfast; however, after Lispro injection, insulin levels in-
creased rapidly and returned close to baseline levels before
lunch. There was a second insulin peak of similar magnitude
after Lispro administration with lunch, and values declined
to below baseline within 4 h. After R!N administration,
insulin levels increased gradually, peaked at 1100 h, and then
declined slowly throughout the remainder of the study pe-
riod. The total insulin AUC did not differ between treatment
days (P # 0.44; Fig. 1B). This was expected because subjects
received the same total number of units of insulin on each
treatment day.
Glucose
Baseline plasma glucose concentrations tended to be lower
on the Lispro treatment day, but the difference was not
statistically significant (P # 0.06, Fig. 2A). Postprandial glu-
cose levels were lower on the Lispro treatment day and the
difference was most pronounced during the 2–3 h after
breakfast and lunch. The total glucose AUC was approxi-
mately 60% lower on the Lispro treatment day, compared
with the R!N treatment day (P# 0.024, Fig. 2B). This finding
indicates significantly improved glycemic control and glu-
cose disposalwith Lispro, comparedwith conventional R!N
treatment, even though the total calories and amount of
carbohydrate ingested and the number units of insulin re-
ceived were equivalent in both conditions.
Leptin
Baseline fasting plasma leptin concentrations tended to be
somewhat higher in these young women with T1DM than
those reported in a group of nondiabetic women with a
similar mean BMI and body adiposity (BMI 23.4 " 0.46
kg/m2, body fat 27.4 " 1.12%) (17). Mean baseline leptin
concentrations were not different on the 2 treatment days;
however, leptin levels varied widely between subjects, rang-
ing from 3 to 46 ng/ml. Due to this variability, the change of
leptin ($[Leptin]; Fig. 3A) from the morning nadir was cal-
culated, as previously described (21). This method allows
direct comparison of subjects with differing baseline adipos-
ity and leptin levels, and the $[Leptin] has been implicated
as an important regulator of central energy homeostasis (21).
The early patterns of circulating leptin were similar after
each of the insulin treatments, with morning nadir levels
occurring at about 1000–1100 h, as previously reported in
nondiabetic subjects (21). On the Lispro study day, plasma
leptin increased approximately 4 ng/ml above nadir levels
by 1700 h. On the R!N regimen, the increase of leptin was
consistently lower, with mean $[Leptin] less than 1 ng/ml
for all but three time points. After lunch, when differences in
FIG. 1. A, Plasma insulin concentrations over a 10-h period (0800–
1800 h) in 10 female subjectswithT1DMreceivingLispro insulinwith
breakfast and lunch or R!N with breakfast. Identical meals were
consumed and the same total number of units of insulin was given on
each study day. B, The AUC for plasma insulin concentrations above
baseline levels over 9 h after breakfast in 10 female subjects with
T1DM receiving Lispro insulin or R!N.
FIG. 2. A, Plasma glucose concentrations over a 10-h period (0800–
1800 h) in 10 female subjects with T1DM receiving Lispro insulin or
R!N. B, The AUC for plasma glucose concentrations above baseline
levels over 9 h in 10 female subjects with T1DM receiving Lispro
insulin or R!N. *, P # 0.024 for Lispro treatment, compared with
R!N.
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insulin patterns and glucose disposal were most apparent,
the mean $[Leptin] did not significantly change from nadir
in the R!N treatment for either the 1200–1800 h time period
(0.7 " 0.5; ns) or the final hour of observation (1700–1800 h
time interval, 1.0 " 0.7; ns; Fig. 3B). However, a very sig-
nificant increase in leptin was observed on the Lispro treat-
ment day during both time periods (2.6 " 0.7 for the 1200–
1800 h time interval; P % 0.0025; and 3.9 " 1.0 for the 1700–
1800 h time interval; P% 0.0025). The mean $[Leptin] on the
Lispro day was also significantly higher than on the R!N
treatment day during both the 1200–1800 h interval (P #
0.024) and during the 1700–1800 h interval (P # 0.026; Fig.
3B). Similarly, the total leptin AUC (above morning nadir
levels) over the entire 10-h period was more than two times
larger on the Lispro treatment day (33.6" 5.7 ng/ml per 10 h)
than on the R!N treatment day (14.7 " 5.0 ng/ml per 10 h;
P# 0.003 vs. Lispro) (Fig. 3C). Postprandial leptin responses
and the AUC on the Lispro treatment day were similar to
those observed over this same 10-h period in nondiabetic
womenwith normal endogenous insulin secretion (35.5" 4.9
ng/ml per 10 h (21).
Ghrelin
Baseline fasting plasma ghrelin concentrations (mean of
0800, 0830, and 0900 h samples) in these females with T1DM
were not different between Lispro (183.0 " 25.9 pg/ml) and
R!N (202.6 " 37.3 pg/ml) treatment days. Ghrelin concen-
trations decreased 1–3 h after breakfast on both insulin reg-
imens and then rose gradually until lunch (Fig. 4A), similar
to reports in nondiabetic individuals (22). Postprandial sup-
pression of ghrelin after breakfast tended to be greater on the
Lispro than the R!N day, but this difference did not achieve
statistical significance (P # 0.119). In contrast, the suppres-
sion of ghrelin after lunch was significantly more pro-
nounced at 30 (P# 0.004), 75 (P# 0.006), 90 (P# 0.002), and
120 min (P# 0.05) when the subjects received Lispro insulin
with lunch, comparedwith the conventional R!N treatment.
On the Lispro treatment day, the suppression of ghrelin was
apparent 30 min after lunch and was sustained significantly
longer, taking an average of 169 min to return to prelunch
levels, compared with 52 min with R!N treatment (P #
0.008). Whereas the 10-h AUC for plasma ghrelin concen-
trations was not significantly different on the 2 treatment
days, the decrease of plasma ghrelin levels during the 2.5-h
period after lunch was significantly different, with the 2.5-h
FIG. 3. A, The $[Leptin] concentrations over morning nadir levels over
a 10-h period (0800–1800 h) in 10 female subjects with T1DM receiving
Lispro insulin or R!N. B, The $[Leptin] concentrations over morning
nadir levels during the periods from 1200 to 1800 h and from 1700 to
1800h in10 femalesubjectswithT1DMreceivingLispro insulinorR!N.
*, P % 0.05 for Lispro treatment, compared with R!N. C, The AUC for
plasma leptin concentrations above morning nadir levels over 10 h in 10
female subjectswithT1DMreceivingLispro insulinorR!N.*,P#0.003
for Lispro treatment, compared with R!N.
FIG. 4. A, Plasma ghrelin concentrations over a 10-h period (0800–
1800 h) in 10 female subjects with T1DM receiving Lispro insulin or
R!N. B, The AUC for plasma ghrelin concentrations from prelunch
levels during the 2.5-h period after lunch in 10 female subjects with
T1DM receiving Lispro insulin or R!N. *, P % 0.01 for Lispro treat-
ment, compared with R!N.
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AUC being positive on the R!N day and negative on the
Lispro day (P # 0.008; Fig. 4B).
Discussion
There is evidence that insulin-stimulated glucose disposal
is involved in the postprandial regulation of both leptin and
ghrelin. Recent advances in insulin therapy, including rapid-
acting insulin analogs, allow patients with diabetes to more
closely match the kinetics of normal, endogenously secreted
insulin. More physiological insulin responses to meals result
in improved glucose disposal and may normalize the regu-
lation of hormones involved in the control of energy ho-
meostasis.We hypothesized that patientswith T1DM treated
at mealtime with rapid-acting Lispro insulin would have
increased leptin production and a greater suppression of
ghrelin in the postprandial period, compared with a more
conventional R!N treatment.
As expected, administration of Lispro insulin with break-
fast and lunch resulted in two rapid-onset peaks in circu-
lating insulin concentrations, whereas a single injection of
R!N produced a single peak of slower onset and more
sustained duration. Although total insulin exposure over the
course of the day did not differ between the two insulin
treatments, Lispro treatment substantially improved glyce-
mic control, as in previous reports (23, 24). This observation
is consistent with the importance of early insulin secretion in
the control of meal-induced glucose excursion and day-long
glycemia (25).
In nondiabetic subjects, circulating leptin concentrations
exhibit a diurnal pattern with a nadir in the midmorning and
a late-night nocturnal peak (11, 21). The diurnal leptin pat-
tern is dependent on insulin responses to meals and is there-
fore influenced by meal timing (21) and dietary macronu-
trient composition (8). Meal-induced insulin secretion
increases plasma leptin concentrations within 3–6 h (21).
Insulin plays a major role in the regulation of leptin pro-
duction, stimulating the transcriptional activity of the leptin
promoter, increasing leptin gene expression and elevating
circulating leptin concentrations. These effects are all medi-
ated by insulin’s actions to promote glucose uptake and
oxidative metabolism in adipocytes (26–28). Thus, improved
glycemic control is expected to result in increased glucose
use by adipose tissue, enhance leptin production, and po-
tentially improve body weight regulation.
On the day that Lispro was administered, the rise of leptin
was three to four times larger and the leptin AUC was in-
creased by 2.5 times, compared with a single morning in-
jection of R!N. This difference was observed despite similar
overall insulin exposure and intake of identical meals on the
2 study days. These results suggest that administration of
Lispro insulin with meals enhances postprandial glucose use
in adipose tissue, leading to increased leptin production.
Improved leptin production augments the amplitude of the
diurnal pattern of circulating leptin levels, which has been
implicated as a signal in the long-term regulation of energy
balance and body adiposity (29).
In nondiabetic individuals, plasma ghrelin concentrations
increase before meals and decrease after meals (22), Admin-
istration of exogenous ghrelin enhances appetite and in-
creases food intake in humans (15) and decreases fat use,
resulting in weight gain in rodents (30). Postprandial sup-
pression of ghrelin is apparent within 30 min and reaches the
nadir 1–2 h after a meal (31). There is evidence, consistent
with the results of this study, that insulin is involved in the
postprandial suppression of ghrelin (32–34). Circulating
ghrelin concentrations are increased in the presence of hy-
perglycemia in streptozotocin-induced diabetic rats (35) as
well as humans with T1DM (33). Insulin treatment in rats
with streptozotocin-induced diabetes significantly reduces
ghrelin levels (35). Correction of insulin deficiency in indi-
viduals with T1DM also inhibits ghrelin, whereas insulin
deficiency results in a lack of postprandial suppression of
ghrelin (33). Indeed, increased ghrelin signaling in T1DMhas
been implicated as a contributing factor in the pathogenesis
of diabetic hyperphagia (36). Ghrelin levelsmay also respond
to changes in body weight via changes in insulin levels as-
sociated with body adiposity (37). Thus, dysregulation of
ghrelin appears to be a potential contributing factor to the
overrepresentation of overweight and obesity in T1DM.
As expected, plasma ghrelin levels decreased after break-
fast in these T1DM subjects when they were treated with
insulin at the onset of the meal. However, the postprandial
suppression after lunch was significantly more pronounced
after the short-acting Lispro insulin with lunch than on the
day the subjects received R!N administered only at break-
fast. Given the similar degree of overall insulin exposure and
nutrient ingestion, yet the clearly different levels of glucose
disposal and use, these results suggest that the decrease in
ghrelin levels in response to insulin is mediated, at least in
part, by insulin effects on cellular glucose uptake and/or
metabolism as opposed to an effect of insulin per se.
Differentiating the effects of glucose from insulin on
ghrelin secretion, as well as leptin production, has been chal-
lenging. Many studies have used the glycemic clamp, during
which insulin and glucose are simultaneously administered
iv. Flanagan et al. (32) reported a decrease in circulating
ghrelin after administration of insulin and glucose, and the
authors suggest that insulin may inhibit ghrelin secretion,
independently of glucose. Because insulin and glucose were
administered together, however, it is not possible to deter-
mine whether the observed suppression of ghrelin secretion
was due to direct effects of insulin or its effects on glucose
metabolism. In healthy subjects, coinfusion of supraphysi-
ological levels of insulin with glucose decreased plasma gh-
relin concentrations by approximately 50% below baseline
levels, whereas infusion of glucose without insulin, resulting
in elevated plasma glucose levels and increased endogenous
insulin secretion, did not decrease ghrelin concentrations
(38). Because ghrelin was not measured until thirty min after
infusion, early suppression of ghrelin in these insulin-sen-
sitive individuals may have been missed.
In contrast, a recent study in obese individuals using hy-
perinsulinemic euglycemic clamps demonstrated that insu-
lin infusion acutely decreases plasma ghrelin levels in obese
subjects (39). The degree of suppression of ghrelin was re-
lated to insulin-mediated glucose use. These data support the
hypothesis that insulin regulates ghrelin secretion via its
effects on glucose uptake and metabolism, similar to the
manner in which insulin regulates leptin production (26). In
Griffen et al. • Lispro Insulin, Leptin, and Ghrelin in T1DM J Clin Endocrinol Metab, February 2006, 91(2):485–491 489
 on February 8, 2006 jcem.endojournals.orgDownloaded from 
the present study, overall insulin exposure and nutrient in-
gestion were similar on both treatment days; however, glu-
cose disposal, the stimulation of leptin, and the postprandial
suppression of ghrelin were all substantially greater on the
day the subjects received Lispro insulin.
Conclusions
Leptin and ghrelin have major roles in the regulation of
energy balance and fuel use (8), and normal regulation of
these hormones is required to maintain energy homeostasis
in humans (9, 10). Insulin exerts direct central nervous sys-
tem effects on energy metabolism and regulates circulating
leptin and ghrelin concentrations. The results of the present
study support the hypothesis that insulin’s effects to increase
leptin production and suppress ghrelin secretion are, at least
in part, meditated by enhanced glucose uptake and metab-
olism in response to insulin. Rapid-acting Lispro insulin
administered with meals, compared with more conventional
R!Nregimens, increase leptin production and enhance post-
prandial suppression of ghrelin. Although this study did not
profile 24-h leptin and ghrelin, the patterns of daytime leptin
and ghrelin on the Lispro treatment day were much more
similar to those previously reported in nondiabetic individ-
uals (21, 31, 40). It remains to be determined in long-term
studies whether insulin regimens that improve postprandial
glycemic control, and normalize the regulation of leptin and
ghrelin, will ultimately provide better long-term control of
body weight/adiposity in patients with T1DM.
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